Prognosis for Recurrent AML with CBFB Rearrangement 20 Months Post-Transplant
This patient has a grave prognosis with an expected median survival of 3-6 months, as this represents a third recurrence of AML occurring 20 months after stem cell transplant—a timeframe associated with only 4-12% three-year survival even at first relapse. 1, 2
Interpretation of Cytogenetic Findings
The current studies reveal several critical prognostic features:
CBFB gene rearrangement (42% of cells): While inv(16)/CBFB-MYH11 AML is classified as favorable-risk at initial diagnosis, this favorable biology is completely negated by multiple relapses and post-transplant recurrence 3, 4, 1
Extra RUNX1T1 signal (7% of cells): This represents clonal evolution and chromosomal instability, indicating more aggressive disease biology that was not present in previous specimens 1
New der(1;18) translocation: This unbalanced translocation results in gain of 1q and loss of 18p. Jumping translocations of chromosome 1q are rare cytogenetic phenomena associated with high risk of transformation and regarded as independent poor prognostic factors 3
Trisomy 8 clone (2/20 cells): This secondary abnormality, while present in previous specimens, contributes to intermediate-risk features 3
Absence of TP53 deletion: This is the only potentially favorable finding, as TP53 abnormalities confer the worst prognosis in relapsed AML 3, 1
Critical Adverse Prognostic Factors
Multiple converging factors predict extremely poor outcomes:
Post-transplant relapse at 20 months: Patients relapsing within 20 months after stem cell transplant have 3-year survival probabilities of only 4-12% even at first relapse 1, 2
Third recurrence: By the third recurrence, patients have exhausted standard salvage options, developed resistant disease biology, and accumulated treatment-related organ damage 1
Age 64 years: Increasing age is an independent adverse prognostic factor that predicts higher treatment-related mortality 3, 5
Clonal evolution: The appearance of new cytogenetic abnormalities (der(1;18) and extra RUNX1T1 signals) indicates genetic instability and treatment resistance 3, 1
Disease not in remission: The presence of 42% cells with CBFB rearrangement indicates active disease, which carries significantly worse outcomes than relapse in remission 6
Expected Clinical Course
The median overall survival from this point is approximately 4 months, with the following trajectory:
30-day mortality risk: Intensive salvage chemotherapy carries 14% or higher 30-day mortality in heavily pretreated patients 1
Most likely response: At best, brief partial response or stable disease with current therapy, not durable remission 1
Infection risk: Given prior transplant and current treatment, expect high rates of infectious complications (84% any grade infections with venetoclax-azacitidine) 1
Quality of life: Progressive decline with treatment-related toxicities likely outweighing benefits 1, 2
Treatment Expectations and Monitoring
If pursuing disease-directed therapy:
Response assessment timing: Do not evaluate bone marrow before 8-12 weeks (2-3 cycles) of azacitidine-venetoclax, as hypomethylating agents require time to demonstrate efficacy 1
Bone marrow evaluation: Should occur after hematologic recovery following cycle 2-3 1
Supportive care requirements: Mandatory antibiotic and antifungal prophylaxis given 30-61% febrile neutropenia rates 1
Realistic Outcome Probabilities
Based on the evidence:
- Complete remission: <10% probability of achieving durable CR 1, 2
- Median survival: 3-6 months from current relapse 1, 2
- 1-year survival: <5% 1, 2
- Long-term survival: Essentially 0% 1, 2
Critical Management Recommendations
Early palliative care involvement is essential and should occur immediately, not as an afterthought. 1, 2
Quality of life considerations should guide all treatment decisions at this stage, with realistic discussions about:
- The extremely low probability of meaningful disease control 1
- High likelihood of treatment-related complications without survival benefit 1, 2
- Goals of care and advanced care planning 2
- Hospice referral as disease progresses 2
The combination of third recurrence, post-transplant relapse at 20 months, clonal evolution with new cytogenetic abnormalities, and age 64 years creates a constellation of adverse factors that predict survival measured in months, not years. 3, 5, 1, 2